BAY 3547926
Alternative Names: BAY-3547926Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Bayer
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 08 Jan 2025 Preclinical trials in Liver cancer in USA (Parenteral)
- 08 Jan 2025 Bayer plans a phase I trial for Liver cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Belgium, Canada, Finland, Spain and the United Kingdom (Parenteral) March 2025 (NCT06764316)